Severe Aplastic Anemia
The management of severe aplastic anemia (AA) evolved rapidly for these 2 decades. The advances in the treatment of AA have largely been the result of analyses of large registration data and prospective collaborative studies. Especially, SAA working group in European Group for Blood and Marrow Transplantation (EBMT) has contributed to much of progress in this field. In Europe and the United State, aplastic anemia is a rare disease, with annual incidence ranging from 1.0 to 2.0 per million per year. However, in Asia, AA is much more common. In several countries, AA is the most frequent indication for hematopoietic stem cell transplantation.
Immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine has been an alternative treatment for patients who do not have suitable donors. Until now, horse ATG has been commonly used for the treatment of AA in Asia and Europe. However, the production of horse ATG has been discontinued and replaced by rabbit ATG. Because there is no large study to evaluate the effectiveness of rabbit ATG for treatment of AA, it is urgently necessary to conduct a dose finding study for rabbit ATG. To obtain the result, a large number of patients are required. Because this is a common issue in Asia and Europe, the SAA working group in EBMT proposes collaboration with APBMT group.
Based on these backgrounds, I propose to organize a working group for severe aplastic anemia in APBMT group.
Prof. Seiji Kojima MD, PhD
?The First Chairman of the Severe Aplastic Anemia Working Group
Minutes of Severe Aplastic Anemia Working Group Meetings are available here Click on the following links to download.
Note: Access to the document links within the Minutes pages is restricted to members only and requires a password.
Chairman: Hoon Kook (Korea)
|Yoshihisa Kodera||Japan||Aichi Medical University|
|Asahito Hama||Japan||Nagoya University|
|Dae Chul Jeong||Korea||Catholic University of Korea|
|Kook Hoon||Korea||Chonnam National University|
|Zhang Feng Kui||China||Institute of Hematology & Blood Disease Hospital|
|Wang Yue||China||Jilin University|
|Honorata G Baylon||Philippines||Luke's Medical Center, Blood and Marrow Transplant Center|
|Tai-ju Hwang||Korea||Chonnam National University,|
|Jong Wook Lee||Korea||Catholic University of Korea|
|Minako Iida||Japan||Aichi Medical University|
|Hideki Muramatsu||Japan||Nagoya University|
|Tahir Sultan Shamsi||Pakistan||National Institute of Blood Disease & Bone Marrow Transplantation|
|Shinji Nakao||Japan||Kanazawa University|
|Surapol I ssaragrisil||Thailand||Mahidol University|
|Michelle POON||Singapore||National University Hospital|
|Xiaofan Zhu||China||Institute of Hematology & Blood Disease Hospital|
|Tasneem Farzana||Pakistan||National Institute of Blood Disease & Bone Marrow Transplantation|
|Akira Shimada||Japan||Nagoya University|
|Tnag Jing-Yan||China||Shanghai Children's medical Center|
|Teeraya Pualvilai||Thailand||Mahidol University|
|Yoshiyuki Takahashi||Japan||Nagoya University|
|Shinichiro Okamoto||Japan||Keio University|
|Guangsheng HE||China||Jiangsu Institute of Hematology, Clinical Dept. of Hematology of First Affiliated Hospital of Soochow University|
|Lily WONG Lee Lee||Malaysia||Head of Dept. of Hematology, Queen Elizabeth Hospital|
|Pimjai Niparuck||Thailand||Mahidol University|
|Mickey Koh||Singapore||Deputy Director, Center of Transfusion Medicine Health Sciences Authority, Head-Bone Marrow Transplantation St George's Hospital and Medical School|